drugset / Trial / NCT03551496

The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia

NCT03551496 ↗

Phase 3 Completed 201 enrolled Boston Scientific Corporation
RandomizedParallel-groupSingle-blindTreatment

Summary

Single phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs. percutaneous transluminal angioplasty (PTA).

Timeline

Start
2018-08-31
Primary completion
2022-04-21
Completion
2023-12-20

Outcome

Missed primary endpoint

paper The 12-month primary patency rates were 68.0% for the DES group and 76.0% for the PTA group (Psuperiority = 0.8552). PMID 37844137 ↗

paper The MAE-free rates were 91.6% and 95.3%, respectively (Pnoninferiority = 0.0433). PMID 37844137 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule — —

Indications